IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor

Leukemia

Volumn 11, Issue 1, 1997, Pages 22-30

  Frankel, A E ^a,b   Fu, T ^a   Burbage, C ^a   Chandler, J ^a   Willingham, M C ^a   Tagge, E P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Fusion toxin; IL2 receptor; Ricin

Indexed keywords

ASIALOFETUIN; GALACTOSE; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LECTIN; RICIN;

ARTICLE; CYTOTOXICITY; DISSOCIATION CONSTANT; HUMAN; HUMAN CELL; IMMUNOAFFINITY CHROMATOGRAPHY; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL;

EID: 0031056677     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400517     Document Type: Article

References (13)

1. Takeshita T, Asao H, Ohtani K, Ishii N, Kumaki S, Tanaka N, Munakata H, Kakamura M, Sugamura K. Cloning of the γ chain of the human IL-2 receptor. Science 1992; 257: 379-382.
2. Waldmann T. The multi-subunit interleukin-2 receptor. Annu Rev Biochem 1989; 58: 875-911.
3. Williams D, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom T, Murphy J. Diphtheria toxin receptor binding domain substitution with interleukin 2: genetic construction and properties of a diphtheria toxin related interleukin-2 fusion protein. Protein Eng 1987; 1: 493-498.
4. Williams D, Snider C, Strom T, Murphy J. Structure/function analysis of IL2 toxin (DAB486-IL2): fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J Biol Chem 1990; 265: 11885-11889.
5. Strom T, Kelley V, Murphy J, Nichols J, Woodworth T. Interleukin2 receptor-directed therapies: antibody- or cytokine-based targeting molecules. Adv Nephrol 1994; 23: 347-356.
6. Foss F, Kuzel T. Experimental therapies in the treatment of cutaneous T-cell lymphoma. Hematol/Oncol Clin N Am 1995; 5: 1127-1137.
7. Lorberboum-Galski H, Chaudhary V, Adhya S, Pastan I. Cytotoxic activity of an interleukin 2 Pseudomonas exotoxin chimeric protein produced in E. coli. Proc Natl Acad Sci USA 1994; 85: 1922-1926.
8. Kreitman R, Pastan I. Recombinant single-chain immunotoxins against T and B cell leukemias. Leuk Lymphoma 1994; 13: 1-10.
9. Reiter Y, Kreitman R, Brinkmann U, Pastan I. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int J Cancer 1994; 58: 142-149.
10. Kreitman R, Schneider W, Queen C, Tsudo M, FitzGerald D, Waldmann T, Pastan I, Mik-β1 (Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the β-chain of the IL2 receptor. J Immunol 1992; 149: 2810-2815.
11. Endo Y, Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J Biol Chem 1987; 262: 8128-8130.
12. Eiklid K, Olsnes S, Pihl A. Entry of lethal doses of abrin, ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res 1980; 126: 321-326.
13. O'Day S, Fidias P. Ariniello P, Kolesar C, Stageman C, Braman G, Esseltine D, Freedman A, Nadler L, Grossbard M. Phase II trial of bolus infusion anti-B4-blocked ricin (anti-B4-bR) in patients with B-cell non-Hodgkin's lymphoma (NHL). Proc ASCO 1996; 15: 445.